Smith S E, Acton L, Sharp T
University of Oxford, Department of Clinical Pharmacology, Radcliffe Infirmary, UK.
Psychopharmacology (Berl). 1997 Sep;133(1):85-94. doi: 10.1007/s002130050375.
The behavioural effect of dopamine D1-like receptor agonists (SKF 38393, SKF 81297) and a D2-like receptor agonist (quinpirole), administered alone and in combination, was tested in rats pretreated with a single injection of an NMDA antagonist (MK-801, CPP) or vehicle. Agonist-induced behaviour was monitored by automated activity meters and direct observation using a checklist scoring method. Pretreatment with MK-801 (0.05 mg/kg, SC, 30 min) had no significant effect (compared to controls) on the behavioural response to SKF 38393 (7.5 mg/kg SC), SKF 81297 (0.2 mg/kg SC) or quinpirole (0.1 and 0.25 mg/kg SC) administered alone. In contrast, MK-801 markedly increased locomotion (activity counts and scores) induced by co-administration of a D1-like plus a D2-like agonist [SKF 38393 (7.5 mg/kg) plus quinpirole (0.25 mg/kg), SKF 81297 (0.2 mg/kg) plus quinpirole (0.1 mg/kg)]. The behavioural response to the non-selective dopamine agonist apomorphine (0.5 mg/kg SC) was also enhanced by MK-801. Pretreatment with CPP (0.1 mg/kg SC, 30 min) also significantly increased the locomotor response to co-administration of SKF 38393 plus quinpirole administered alone, but had no effect on the behavioural response to separate injection of these agonists. MK-801 (0.05 mg/kg SC, 30 min) also enhanced the behavioural response to bilateral injection into the nucleus accumbens of SKF 38393 plus quinpirole (1.0 plus 0.4 microgram/side, respectively). These data suggest that in the intact rat, the enhancement of dopamine-mediated behaviour by either MK-801 or CPP requires concomitant stimulation of D1-like and D2-like receptors, possible located within the nucleus accumbens. The effect of these NMDA antagonists on dopamine function is similar to that of repeated electroconvulsive shock (ECS), indicating that one of the actions of ECS may be to reduce NMDA receptor function.
单独及联合给予多巴胺D1样受体激动剂(SKF 38393、SKF 81297)和D2样受体激动剂(喹吡罗)对预先单次注射N-甲基-D-天冬氨酸(NMDA)拮抗剂(MK-801、CPP)或赋形剂的大鼠的行为影响进行了测试。通过自动活动计及使用清单评分法直接观察来监测激动剂诱导的行为。预先给予MK-801(0.05mg/kg,皮下注射,30分钟)对单独给予SKF 38393(7.5mg/kg皮下注射)、SKF 81297(0.2mg/kg皮下注射)或喹吡罗(0.1和0.25mg/kg皮下注射)的行为反应无显著影响(与对照组相比)。相反,MK-801显著增加了联合给予D1样和D2样激动剂[SKF 38393(7.5mg/kg)加喹吡罗(0.25mg/kg)、SKF 81297(0.2mg/kg)加喹吡罗(0.1mg/kg)]所诱导的运动(活动计数和评分)。MK-801也增强了对非选择性多巴胺激动剂阿扑吗啡(0.5mg/kg皮下注射)的行为反应。预先给予CPP(0.1mg/kg皮下注射,30分钟)也显著增加了对联合给予SKF 38393加喹吡罗单独给药的运动反应,但对这些激动剂单独注射的行为反应无影响。MK-801(0.05mg/kg皮下注射,30分钟)也增强了向伏隔核双侧注射SKF 38393加喹吡罗(分别为1.0加0.4微克/侧)的行为反应。这些数据表明,在完整大鼠中,MK-801或CPP增强多巴胺介导的行为需要同时刺激D1样和D2样受体,可能位于伏隔核内。这些NMDA拮抗剂对多巴胺功能的影响与重复电惊厥休克(ECS)相似,表明ECS的作用之一可能是降低NMDA受体功能。